Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secretin - ChiRhoClin

Drug Profile

Secretin - ChiRhoClin

Alternative Names: ChiRhoStim; Synthetic secretin diagnostics - ChiRhoClin

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChiRhoClin
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency; Pancreatic cancer
  • No development reported Pain
  • Discontinued Pancreatitis

Most Recent Events

  • 27 Sep 2018 ChiRhoClin plans the phase II SNAP trial for acute Pancreatitis in the US (IV) (NCT03686618)
  • 15 Mar 2016 Biomarkers information updated
  • 09 Apr 2012 Registered for Pancreatic cancer (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top